

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

**ANNOUNCEMENT OF
BOARD MEETING (DATE RESCHEDULED)
AND
DELAY IN PUBLICATION AND DESPATCH
OF ANNUAL REPORT FOR THE YEAR**

Reference is made to the announcement of the Company dated 7 March 2022 in relation to the forthcoming Board meeting. Unless otherwise defined in this announcement, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Company dated 7 March 2022.

Due to the delay in the completion of the auditing work of annual results by the auditor of the Company as a result of the COVID-19 pandemic, the Board hereby announces that the forthcoming Board meeting has been rescheduled to be held on 13 April 2022, details such as the venue of the meeting and matters to be discussed are the same as those set out in the announcement of the Company dated 7 March 2022.

The Company expects that there will be a delay in the publication of the annual report for the year on the website established by the Stock Exchange for GEM and the despatch of the annual report for the year to the holders of shares (“**Shareholders**”), and it is unlikely to be completed by 31 March 2022 (i.e. the time that the annual report should be despatched to the Shareholders by the Company as required under the Rules Governing the Listing of Securities on GEM of the Stock Exchange (“**GEM Listing Rules**”). The Company expects that the annual report for the year will be published and despatched to the Shareholders no later than 22 April 2022.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
21 March 2022

As at the date of this announcement, the executive directors of the Company are Ms. Sun Li, Mr. Hao Zhihui and Mr. He Xin; the non-executive directors of the Company are Mr. Cao Aixin, Dr. Li Ximing and Ms. Li Xueying; the independent non-executive directors of the Company are Mr. Li Xudong, Mr. Wang Yongkang and Ms. Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Listed Company Information” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.